Eikon Therapeutics (EIKN) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eikon Therapeutics is the larger company by market cap ($406.2 million vs $382.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EIKN | KYTX |
|---|---|---|
| Share price | $7.50 | $6.18 |
| Market cap | $406.24M | $382.19M |
| 1-day change | -0.53% | +0.16% |
| YTD return | — | -34.26% |
| 1-year return | — | -13.93% |
| EPS (TTM) | $-8.51 | $-2.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.40 | $13.67 |
| 52-week low | $7.02 | $5.96 |
| Distance from 52-week high | -56.90% | -54.79% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +228.00% | +391.91% |
| Average volume | 497.76K | 903.83K |
| Shares outstanding | 54.17M | 61.84M |
| Employees | 384 | 149 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
EIKN vs KYTX FAQ
Which is bigger, Eikon Therapeutics or Kyverna Therapeutics?
Eikon Therapeutics (EIKN) is larger, with a market capitalization of $406.24M compared with $382.19M for Kyverna Therapeutics (KYTX).
Are Eikon Therapeutics and Kyverna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.